This analysis examines the historical and forecast performance for AstraZeneca in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. ( http://www.bharatbook.com/detail.asp?id=70240&rt=AstraZeneca-PharmaVitae-Profile.html )
 
 Features and benefits - Gain insight into AstraZeneca's strategic outlook across the next 6 years. Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source. Highlights - Strategic insight into the prospects for AstraZeneca over the next six years. Picking out key strengths, weaknesses, opportunities and threats and evaluating the company's prescription pharmaceuticals outlook using a variety of cuts of the historical and forecast sales.
 
 Your key questions answered - Benchmark AstraZeneca's performance against key rivals in the prescription pharmaceutical sector. Assess the importance of Crestor, set to become the industry's biggest-selling product, to AstraZeneca's forecast growth performance. Analyse AstraZeneca's high level of anticipated exposure to flagship product patent expiries through to 2015 and the impact on company strategy
 
 For more information kindly visit : http://www.bharatbook.com/detail.asp?id=70240&rt=AstraZeneca-PharmaVitae-Profile.html
 
 Related Reports
 
 Abbott Laboratories: PharmaVitae Profile 
 
 Mitsubishi Tanabe Pharma Corp.: PharmaVitae Profile 
 
 -30-
 
 Or
 
 Contact us at :
 
 Bharat Book Bureau
 Tel: +91 22 27578668
 Fax: +91 22 27579131
 Email: info@bharatbook.com 
 Website: www.bharatbook.com 
 Follow us on twitter: http://twitter.com/#!/BharatBook